gamma-H2AX: Can it be established as a classical cancer prognostic factor?

被引：73
作者：
Palla, Viktoria-Varvara [1 ]
Karaolanis, Georgios [2 ]
Katafigiotis, Ioannis [3 ]
Anastasiou, Ioannis [3 ]
Patapis, Paul [4 ]
Dimitroulis, Dimitrios [5 ]
Perrea, Despoina [5 ]
机构：
[1] Diakonie Klinikum Schwabisch Hall, Dept Obstet & Gynecol, Schwabisch Hall, Germany
[2] Laikon Gen Hosp, Med Sch Athens, Dept Surg 1, Vasc Unit, Athens, Greece
[3] Univ Athens, Laiko Hosp, Univ Urol Clin 1, Athens, Greece
[4] Univ Athens, Attikon Gen Hosp, Dept Surg 3, Athens, Greece
[5] Univ Athens, Laiko Hosp, Dept Surg 2, Athens, Greece
来源：
TUMOR BIOLOGY | 2017年 / 39卷 / 03期
关键词：
gamma-H2AX; cancer; prognosis; histone; DNA damage; DOUBLE-STRAND BREAKS; PHOSPHORYLATED HISTONE H2AX; DNA-DAMAGE; GENOMIC INSTABILITY; POOR-PROGNOSIS; UV-IRRADIATION; IN-VIVO; EXPRESSION; REPAIR; MARKER;
D O I：
10.1177/1010428317695931
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Double-strand breaks are among the first procedures taking place in cancer formation and progression as a result of endogenic and exogenic factors. The histone variant H2AX undergoes phosphorylation at serine 139 due to double-strand breaks, and the gamma-H2AX is formatted as a result of genomic instability. The detection of gamma-H2AX can potentially serve as a biomarker for transformation of normal tissue to premalignant and consequently to malignant tissues. gamma-H2AX has already been investigated in a variety of cancer types, including breast, lung, colon, cervix, and ovary cancers. The prognostic value of gamma-H2AX is indicated in certain cancer types, such as breast or endometrial cancer, but further investigation is needed to establish gamma-H2AX as a prognostic marker. This review outlines the role of gamma-H2AX in cell cycle, and its formation as a result of DNA damage. We investigate the role of gamma-H2AX formation in several cancer types and its correlation with other prognostic factors, and we try to find out whether it fulfills the requirements for its establishment as a classical cancer prognostic factor.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 80 条
[1]   Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins [J].
Asakawa, Hideki ;
Koizumi, Hirotaka ;
Koike, Ayaka ;
Takahashi, Makiko ;
Wu, Wenwen ;
Iwase, Hirotaka ;
Fukuda, Mamoru ;
Ohta, Tomohiko .
BREAST CANCER RESEARCH, 2010, 12 (02)
[2]  
Ausio Juan, 2006, Briefings in Functional Genomics & Proteomics, V5, P228, DOI 10.1093/bfgp/ell020
[3]   High throughput evaluation of gamma-H2AX [J].
Avondoglio, Dane ;
Scott, Tamalee ;
Kil, Whoon Jong ;
Sproull, Mary ;
Tofilon, Philip J. ;
Camphausen, Kevin .
RADIATION ONCOLOGY, 2009, 4 :31
[4]   Histone H2AX: A dosage-dependent suppressor of oncogenic translocations and tumors [J].
Bassing, CH ;
Suh, H ;
Ferguson, DO ;
Chua, KF ;
Manis, J ;
Eckersdorff, M ;
Gleason, M ;
Bronson, R ;
Lee, C ;
Alt, FW .
CELL, 2003, 114 (03) :359-370
[5]  
Bassing CH, 2004, CELL CYCLE, V3, P149
[6]  
Bhatia A, 2013, INDIAN J MED RES, V137, P759
[7]   OPINION γH2AX and cancer [J].
Bonner, William M. ;
Redon, Christophe E. ;
Dickey, Jennifer S. ;
Nakamura, Asako J. ;
Sedelnikova, Olga A. ;
Solier, Stephanie ;
Pommier, Yves .
NATURE REVIEWS CANCER, 2008, 8 (12) :957-967
[8]   Multispectral imaging flow cytometry reveals distinct frequencies of ?-H2AX foci induction in DNA double strand break repair defective human cell lines [J].
Bourton, Emma C. ;
Plowman, Piers N. ;
Zahir, Sheba Adam ;
Senguloglu, Gonul Ulus ;
Serrai, Hiba ;
Bottley, Graham ;
Parris, Christopher N. .
CYTOMETRY PART A, 2012, 81A (02) :130-137
[9]   Expression of γ-H2AX in endometrial carcinomas: An immunohistochemical study with p53 [J].
Brunner, Andreas H. ;
Hinterholzer, Susanne ;
Riss, Paul ;
Heinze, Georg ;
Weiss, Katharina ;
Brustmann, Hermann .
GYNECOLOGIC ONCOLOGY, 2011, 121 (01) :206-211
[10]   Immunohistochemical Expression of Survivin and γ-H2AX in Vulvar Intraepithelial Neoplasia and Low-Stage Squamous Cell Carcinoma [J].
Brustmann, Hermann ;
Hinterholzer, Susanne ;
Brunner, Andreas .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2011, 30 (06) :583-590
12345678